Perrigo Company plc · NYSE:PRGO

Perrigo — Deutsche Bank Healthcare Conference 2009

20 slides from Perrigo's conference presentation, May 18, 2009

  1. Slide 1: Deutsche Bank Healthcare Conference May 18, 2009

    Deutsche Bank Healthcare Conference May 18, 2009

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future

  3. Slide 3: Perrigo Financial Performance

    Perrigo Financial Performance -From Continuing Operations 2,000 • Top line growth fueled by 1,800 16% $1,730 both organic and inorganic R = 1,600 C AG 08 $1,499 activities 03 - 20 20 $1,368 Q408 1,400 $1,294 • FY’08 revenue increased 1,200 $362 million, or 26% $1,007 1,000 $898 $834 • FY’08 new prod

  4. Slide 4: Broad Manufacturing Scale

    Broad Manufacturing Scale Facilities Solid dose Liquids Semi-Solids API North 9 Plants 32 Billion Tablets 170 Million Units 60 Million Units America Europe 3 Plants 3 Billion Tablets 65 Million Units 400 tons Middle/ 5 Plants 0.5 Million Tablets 2 Million Units 6 Million Units 450 tons Far East Tota

  5. Slide 5: Consumer Healthcare

    Consumer Healthcare Global Sales of over $1.3 Billion KEY GROWTH DRIVERS • Mass customization Revenue ($ Mill) QUARTERLY PERFORMANCE • Leader Rx to OTC switches $500 • 48 ANDA’s in pipeline $450 • Famotidine Complete $400 $350 • Generic Omeprazole $300 FY'06 FY'07 • Generic Cetirizine $250 FY'08 $20

  6. Slide 6: Magic of Store Brands

    Magic of Store Brands Store Brands provide consumer value while driving retailer profitability National Store Brand Brand Consumer Price $10.00 $7.00 Retail Cost 7.50 3.00 Retail Profit $2.50 $4.00 % Profit 25% 57% Consumer Savings 30% 5

  7. Slide 7: Store Brands Drive Retailer Profit

    Store Brands Drive Retailer Profit Contribution of Store Brand to a Retailer’s Total Category Sales ($) Vol (Units) Profit ($) 90 80 70 Percent 60 50 40 30 20 10 0 Analgesics Cough/Cold Vitamins Smoking 6 Cessation

  8. Slide 8: Perrigo is the Clear Leader in Rx to OTC Switch

    Perrigo is the Clear Leader in Rx to OTC Switch • 61 approvals over the past 30 years Other • Switch Experts: more ANDAs than any OTC Perrigo Participates in 70% of Market company Nearly $10B potential Rx switches in the next 5 years 7

  9. Slide 9: New Products Drive Growth

    OiGpr ad ole delayed release tablets 20, Just One Tablet Prevents & Relieves Heartbum Due to Acid Indigestion Negi um Smoking Aid Stop Smoking Aid PERHIGD = CENTURY ‘High Potency Multtamin/Multinineal Supplement Glucosamine Cone

  10. Slide 10: Power of Perrigo—The Cetirizine Launch

    Power of Perrigo— The Cetirizine Launch On-shelf Bonus & Economy signage Sizes Pharmacy Store Brand Market Share Introduction Kits Brand Promotion Drives 20% Store Brand Awareness 80% Print Ads Perrigo Other Off-shelf Displays 9

  11. Slide 11: Store Brand Cetirizine 10MG Volume Share

    Store Brand Cetirizine 10MG Volume Share - FDMx 60.0% 50.0% 50.7% 49.0% 50.0% 47.4% 47.3% 45.9% 46.0% 43.8% 42.0% 42.6% Volume Share 38.5% 40.0% 37.7% 35.6% 30.0% 27.0% 20.0% 12.6% 10.0% 0.0% 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week End

  12. Slide 12: Power of Perrigo – The Omeprazole Launch

    Power of Perrigo – The Omeprazole Launch • Brand Sales $750M+ • Potential Annual Revenue Of $150 – 200M 11

  13. Slide 13: Perrigo Store Brand Omeprazole Volume Share

    Perrigo Store Brand Omeprazole Volume Share - FDMx 45.0% 40.3% 39.4% 40.0% 38.5% 36.2% 36.8% 35.8% 34.5% 34.7% 33.9% 35.0% 31.2% 30.8% 30.0% 27.5% Volume Share 25.0% 22.0% 20.0% 15.0% 10.0% 4.1% 5.0% 0.0% 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 Week 4 We

  14. Slide 14: All Category Update

    All Category Update Category Dollar % Growth National Brand Dollar % Growth Store Brand Dollar % Growth Total OTC & Nutrition 3.5 Total OTC & Nutrition 0.6 Total OTC & Nutrition 13.3 OTC 2.4 OTC -1.3 OTC 15.9 Analgesics -0.2 Analgesics -2.3 Analgesics 6.4 CCAS 5.4 CCAS 2.4 CCAS 17.5 GI 0.4 GI -6.2 G

  15. Slide 15: Wal-Mart $4 Rollback Program

    Wal-Mart $4 Rollback Program • World’s largest retailer promoting OTC Store Brand • Focus on quality, affordable healthcare • Expectations for increased volume • Similar to Generic Rx program 14

  16. Slide 16: Generic Rx Business

    Generic Rx Business Top 2 Topical Player QUARTERLY PERFORMANCE KEY GROWTH DRIVERS Rev. (Millions) • Top 2 player in topicals $50 • High barrier to entry – $45 clinical endpoints $40 $35 • FY’08 Sales of $161 million FY'06 $30 FY'07 • Key new products $25 FY'08 - Nasacort settlement $20 FY'09 - Olux

  17. Slide 17: Active Pharmaceutical Ingredients

    Active Pharmaceutical Ingredients Rev. QUARTERLY PERFORMANCE KEY GROWTH DRIVERS (Millions) $40 • One of the world’s largest API businesses $35 • Selling to Pharma companies $30 in more than 25 countries FY'06 $25 FY'07 • FY’08 Sales of $150 million $20 FY'08 $15 FY'09 • Focus on complex, differentia

  18. Slide 18: Perrigo – Continually investing in R&D

    Perrigo – Continually investing in R&D Leading Indicator = Growth $85 M illio n s $65 $45 $25 2004 2005 2006 2007 2008 2009E 17

  19. Slide 19: Fiscal 2009 and Future Growth Drivers

    Fiscal 2009 and Future Growth Drivers Growth Corrective Pressures Action Increased Contract Manufacturing Sales Ibuprofen PM - $70MM Brand Sales Nutrition and Pricing Action Acquisitions – Diba, JB Labs, OTC Input to Restore and Unico Pricing improve Famotidine Complete - $90MM Pressure Margins Bran

  20. Slide 20: Perrigo Uniquely Positioned

    Perrigo Uniquely Positioned • Critical Mass in the industry – 35+ billion tablets/caplets per year • Mass customization – 10,000+ SKUs • Focus on Generic Rx topicals with significant barriers to entry • Low cost manufacturing • API business provides vertical integration potential and critical purcha

Perrigo Company — Deutsche Bank Healthcare Conference 2009 on 6ix